Truist Securities Reiterates Buy on AbbVie, Raises Price Target to $210
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has reiterated its Buy rating on AbbVie (NYSE:ABBV) and raised the price target from $195 to $210.
July 26, 2024 | 12:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has reiterated its Buy rating on AbbVie and raised the price target from $195 to $210, indicating strong confidence in the company's future performance.
The reiteration of a Buy rating and an increased price target from a reputable analyst firm like Truist Securities is a strong positive signal for investors. It suggests that the firm has a high level of confidence in AbbVie's future performance, which is likely to drive short-term stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100